Gilead Sciences, Inc.
HealthcareNASDAQ:GILD · NASDAQ Global Select
-$0.73 today
Vol 2.66M · Avg 6.62M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$29.7B of revenue converted into $9.2B of net income for the selected period. Gross margin is 79.3% and net margin is 30.9%, showing how much revenue survives after costs and taxes. EPS is $7.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.4B +2.4% | $28.8B +6.0% | $27.1B -0.6% | $27.3B -0.1% | $27.3B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.2B -0.3% | $6.3B -3.8% | $6.5B +14.9% | $5.7B -14.3% | $6.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $23.2B +3.1% | $22.5B +9.1% | $20.6B -4.7% | $21.6B +4.4% | $20.7B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 78.8% +0.6pp | 78.3% +2.2pp | 76.0% -3.2pp | 79.3% +3.4pp | 75.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $5.8B -1.8% | $5.9B +3.3% | $5.7B +14.9% | $5.0B +8.2% | $4.6B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $5.7B -6.3% | $6.1B +0.0% | $6.1B +7.4% | $5.7B +8.1% | $5.2B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $11.5B -44.8% | $20.8B +60.2% | $13.0B -9.0% | $14.3B +32.5% | $10.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.8B -0.3% | $2.8B +2.7% | $2.7B +28.1% | $2.1B +2.6% | $2.0B | $374.2M | $1.2B | $631.8M |
| EBITDA | $13.6B +206.3% | $4.4B -57.8% | $10.5B +18.6% | $8.9B -21.9% | $11.3B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 46.1% +30.7pp | 15.4% -23.3pp | 38.7% +6.3pp | 32.4% -9.0pp | 41.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $11.7B +604.0% | $1.7B -78.1% | $7.6B +3.8% | $7.3B -26.1% | $9.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 39.7% +34.0pp | 5.8% -22.3pp | 28.0% +1.2pp | 26.9% -9.5pp | 36.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $349.0M +24.2% | $281.0M -25.3% | $376.0M +254.7% | $106.0M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.0B +4.8% | $977.0M +3.5% | $944.0M +1.0% | $935.0M -6.6% | $1.0B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.9B -96.0% | -$972.0M -30.3% | -$746.0M +50.8% | -$1.5B +7.6% | -$1.6B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $9.8B +1319.7% | $690.0M -89.9% | $6.9B +18.0% | $5.8B -29.8% | $8.3B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 33.3% +30.9pp | 2.4% -22.9pp | 25.3% +4.0pp | 21.3% -9.0pp | 30.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.3B +509.5% | $211.0M -83.1% | $1.2B -0.1% | $1.2B -39.9% | $2.1B | $1.3B | -$1.6B | $745.2M |
| Net Income | $8.5B +1672.9% | $480.0M -91.5% | $5.7B +23.4% | $4.6B -26.2% | $6.2B | $4.9B | $4.8B | $4.7B |
| Net Margin | 28.9% +27.2pp | 1.7% -19.2pp | 20.9% +4.1pp | 16.8% -6.0pp | 22.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $7 +1700.0% | $0 -91.6% | $5 +24.0% | $4 -26.2% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $7 +1684.2% | $0 -91.6% | $5 +23.6% | $4 -26.2% | $5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.2B -0.2% | $1.2B -0.1% | $1.2B -0.6% | $1.3B -0.1% | $1.3B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.3B +0.0% | $1.3B -0.2% | $1.3B -0.3% | $1.3B +0.0% | $1.3B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.05B
Novo Nordisk A/S
NYSE:NVO
$196.75B
Amgen Inc.
NASDAQ:AMGN
$190.71B
Pfizer Inc.
NYSE:PFE
$149.18B
Danaher Corporation
NYSE:DHR
$127.48B
Stryker Corporation
NYSE:SYK
$120.34B
Bristol-Myers Squibb Company
NYSE:BMY
$116.57B
GSK plc
NYSE:GSK
$106.57B
Sanofi
NASDAQ:SNY
$106.47B
Boston Scientific Corporation
NYSE:BSX
$69.91B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GILD generate?
Gilead Sciences, Inc. (GILD) reported $29.44B of revenue in fiscal 2025.
Is GILD profitable?
Gilead Sciences, Inc. (GILD) reported $8.51B of net income, with a net margin of 28.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.